Author
Listed:
- Sandra Valle
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Chronic Diseases and Cancer Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS))
- Sonia Alcalá
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Chronic Diseases and Cancer Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS))
- Laura Martin-Hijano
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Chronic Diseases and Cancer Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS))
- Pablo Cabezas-Sáinz
(Universidad de Santiago de Compostela)
- Diego Navarro
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Chronic Diseases and Cancer Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS))
- Edurne Ramos Muñoz
(Biomarkers and Therapeutic Targets Group - IRYCIS)
- Lourdes Yuste
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Chronic Diseases and Cancer Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS))
- Kanishka Tiwary
(Ulm University)
- Karolin Walter
(Ulm University)
- Laura Ruiz-Cañas
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Chronic Diseases and Cancer Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS))
- Marta Alonso-Nocelo
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Chronic Diseases and Cancer Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS))
- Juan A. Rubiolo
(Universidad de Santiago de Compostela)
- Emilio González-Arnay
(Universidad Autónoma de Madrid (UAM))
- Christopher Heeschen
(Spanish National Cancer Research Centre (CNIO)
Shanghai Jiao Tong University School of Medicine)
- Laura Garcia-Bermejo
(Biomarkers and Therapeutic Targets Group - IRYCIS)
- Patrick C. Hermann
(Ulm University)
- Laura Sánchez
(Universidad de Santiago de Compostela)
- Patricia Sancho
(IIS Aragón)
- Miguel Ángel Fernández-Moreno
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER)
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12))
- Bruno Sainz
(Universidad Autónoma de Madrid (UAM) and Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM), CSIC-UAM
Chronic Diseases and Cancer Area 3 - Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS))
Abstract
Pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer death, has a 5-year survival rate of approximately 7–9%. The ineffectiveness of anti-PDAC therapies is believed to be due to the existence of a subpopulation of tumor cells known as cancer stem cells (CSCs), which are functionally plastic, and have exclusive tumorigenic, chemoresistant and metastatic capacities. Herein, we describe a 2D in vitro system for long-term enrichment of pancreatic CSCs that is amenable to biological and CSC-specific studies. By changing the carbon source from glucose to galactose in vitro, we force PDAC cells to utilize OXPHOS, resulting in enrichment of CSCs defined by increased CSC biomarker and pluripotency gene expression, greater tumorigenic potential, induced but reversible quiescence, increased OXPHOS activity, enhanced invasiveness, and upregulated immune evasion properties. This CSC enrichment method can facilitate the discovery of new CSC-specific hallmarks for future development into targets for PDAC-based therapies.
Suggested Citation
Sandra Valle & Sonia Alcalá & Laura Martin-Hijano & Pablo Cabezas-Sáinz & Diego Navarro & Edurne Ramos Muñoz & Lourdes Yuste & Kanishka Tiwary & Karolin Walter & Laura Ruiz-Cañas & Marta Alonso-Nocelo, 2020.
"Exploiting oxidative phosphorylation to promote the stem and immunoevasive properties of pancreatic cancer stem cells,"
Nature Communications, Nature, vol. 11(1), pages 1-19, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18954-z
DOI: 10.1038/s41467-020-18954-z
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18954-z. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.